Scientists consider whether anti-cytokine therapies tocilizumab and anakinra might alleviate disease severity in COVID 19. Tocilizumab (an IL-6 blocker) has been tested with possible benefit. These results have been mixed. Anakinra (an anti-IL-1 medication) as also tested with mixed results. These drugs have been used for macrophage activation syndrome with some success.
Ryo Otsuka, Ken-ichiro Seino. Macrophage activation syndrome and COVID-19. Inflammation and Regeneration, 2020; 40 (1) DOI: 10.1186/s41232-020-00131-w
Thanks to Science Daily:
Hokkaido University. “Cellular-level interactions that lead to the cytokine storm in COVID-19.” ScienceDaily. ScienceDaily, 8 September 2020. <www.sciencedaily.com/releases/2020/09/200908122534.htm>.